3 results about "Early puberty" patented technology

This application relates to the biomedical field and discloses the use of hypothalamic paternal IGF2 as a biomarker in the preparation of products for screening and preventing precocious puberty. Specifically, it discloses the application of reagents for detecting the gene imprinting status and / or expression level of hypothalamic paternal insulin-like growth factor 2 in the preparation of precocious puberty screening products, and the application of substances that inhibit the activation of hypothalamic paternal insulin-like growth factor 2 or reduce its expression level in the preparation of drugs for preventing and treating precocious puberty. This application establishes a link between paternal IGF2 and BPA and high-nutrition-induced precocious puberty for the first time, clarifying its core role in mediating the occurrence of precocious puberty and its early warning value, breaking through the limitations of traditional precocious puberty mechanism research. The proposed intervention program is both specific and practical. Among them, the application of Dabu Yin Wan (a traditional Chinese medicine formula) achieves precise targeting of traditional Chinese medicine in the intervention of precocious puberty, and compared with existing intervention technologies, it has significant advantages such as fewer side effects, strong targeting, and high operability.

The application discloses a self-destroying syringe for treating children's precocious puberty, relates to the field of treating children's precocious puberty and comprises a plunger barrel, a plunger rod arranged in the plunger barrel, an injection needle arranged at the bottom of the plunger barrel and a self-destroying trigger device sleeved outside the plunger barrel, wherein the plunger barrel comprises two semicircular plunger barrels connected with a cylindrical body at one side outer wall, and the two semicircular plunger barrels are clamped with the injection needle in a folded state; the self-destroying trigger device comprises a split power component arranged at the side of the semicircular plunger barrel away from the cylindrical body, a U-shaped frame sleeved outside the semicircular plunger barrel, a split limiting component arranged at the side of the U-shaped frame close to the split power component and a one-way moving component; the bottom of the U-shaped frame is provided with a needle retraction power component, the outer wall of the U-shaped frame is slidably connected with a moving plate, and the outer wall of the moving plate is connected with the cylindrical body. The syringe integrates a reliable one-time self-destroying mechanism on the basis of the conventional injection function and can effectively avoid repeated use.

Disclosed are compositions and methods including Anti-Müllerian Hormone (AMH) receptor binding peptides. The AMH receptor binding peptides can be used, for example, to modify the activity of the AMH receptor. For example, the AMH receptor binding peptides can activate the AMH receptor, such as the AMH receptor 2, thereby mimicking the function of AMH. In other examples, the AMH receptor binding peptides function as AMH receptor antagonists, thereby interfering with the function of endogenous AMH. By modifying the activity of the AMH receptor, the peptides have multiple applications, including for example modification of treatment of precocious puberty in females, delay of natural menopause, preservation of ovarian follicular reserve, contraception, fertility preservation after ovarian cortex transplant, treatment of endometriosis, treatment of cancer and / or cancer prevention, and treatment of polycystic ovary syndrome (PCOS).